The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

M. von Mehren

Consultant or Advisory Role - Novartis

Honoraria - Novartis

M. C. Heinrich

Consultant or Advisory Role - MolecularMD

Stock Ownership - MolecularMD

Research Funding - Arog; ImClone Systems; Novartis

Expert Testimony - MolecularMD

H. Joensuu

Consultant or Advisory Role - Novartis

Honoraria - Novartis

C. D. Blanke

Consultant or Advisory Role - Novartis

Honoraria - Novartis

E. Wehrle

Employment or Leadership Position - Novartis

Stock Ownership - Novartis

G. D. Demetri

Consultant or Advisory Role - Alnylam; Amgen; ARIAD; ArQule; Bayer; Champions Biotechnology; Daiichi Sankyo; EMD Serono; Enzon; Genentech; GlaxoSmithKline; Idera; Infinity; Johnson & Johnson; Kolltan Pharmaceuticals; N-of-One (U); Novartis; Pfizer; Plexxikon; Takeda; ZIOPHARM Oncology

Stock Ownership - Champions Biotechnology; Kolltan Pharmaceuticals; N-of-One ; Plexxikon

Honoraria - Novartis; Pfizer

Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; Infinity; Johnson & Johnson; Novartis; Pfizer

Expert Testimony - ARIAD (U); Bayer (U); Infinity (U); Merck (U); Novartis (U); Pfizer (U)